Lantheus (NASDAQ:LNTH) Price Target Raised to $100.00

Key Points

• Price target raised to $100: Mizuho bumped its Lantheus target from $95 to $100 and kept an "outperform" rating, implying roughly a 9.9% upside from the prior close.
• Q1 beat and constructive guidance: Lantheus reported EPS of $1.46 vs. $1.25 expected and revenue of $377.3M vs. $354.5M, and set FY‑2026 EPS guidance at $5.00–$5.25.
• Analyst view and growth caveat: The stock has a "Moderate Buy" consensus (eight Buys, three Holds) and a $92 consensus price target, but revenue rose just ~1.2% YoY and EPS was slightly below last year, leaving questions about near‑term organic growth.

Lantheus (NASDAQ:LNTH - Get Free Report) had its target price raised by investment analysts at Mizuho from $95.00 to $100.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an "outperform" rating on the medical equipment provider's stock. Mizuho's price objective indicates a potential upside of 9.89% from the company's previous close.

Several other research firms have also commented on LNTH. JonesTrading lowered shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Friday, February 27th. B. Riley Financial reiterated a "buy" rating on shares of Lantheus in a research report on Friday, May 1st. Citigroup reiterated an "outperform" rating on shares of Lantheus in a research report on Friday. The Goldman Sachs Group reiterated a "neutral" rating and issued a $94.00 price target on shares of Lantheus in a research report on Thursday. Finally, Citizens Jmp upped their price objective on shares of Lantheus from $73.00 to $78.00 and gave the company a "market outperform" rating in a research note on Tuesday, February 24th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $92.00.

Lantheus Trading Up 5.6%

Shares of LNTH opened at $91.00 on Friday. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. The firm's 50-day moving average is $79.69 and its two-hundred day moving average is $68.87. Lantheus has a twelve month low of $47.25 and a twelve month high of $93.00. The firm has a market capitalization of $5.92 billion, a P/E ratio of 27.00 and a beta of -0.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same period in the prior year, the business posted $1.53 earnings per share. The firm's revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts predict that Lantheus will post 4.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lantheus

Several institutional investors and hedge funds have recently modified their holdings of the company. Abel Hall LLC lifted its stake in shares of Lantheus by 4.6% during the first quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider's stock valued at $297,000 after buying an additional 172 shares during the period. Smartleaf Asset Management LLC raised its stake in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider's stock worth $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. raised its stake in Lantheus by 30.3% during the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider's stock worth $66,000 after purchasing an additional 230 shares during the period. Vident Advisory LLC raised its stake in Lantheus by 0.5% during the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider's stock worth $2,979,000 after purchasing an additional 230 shares during the period. Finally, United Community Bank raised its stake in Lantheus by 15.6% during the third quarter. United Community Bank now owns 1,815 shares of the medical equipment provider's stock worth $93,000 after purchasing an additional 245 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Key Headlines Impacting Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q1 beat — Lantheus reported EPS of $1.46 vs. consensus $1.25 and revenue of $377.3M vs. $354.5M, showing better‑than‑expected top‑ and bottom‑line performance. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: EPS guidance raised/made constructive — management set FY‑2026 EPS at $5.00–$5.25, slightly above street estimates, signalling confidence in margin and earnings leverage for the year. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analyst/valuation commentary cites FDA approval catalysts — coverage notes upcoming regulatory milestones and pipeline readouts that could be upside catalysts for the stock beyond the quarter. Lantheus Holdings (LNTH) Valuation Check After Q1 Earnings Beat And FDA Approval Catalysts
• Neutral Sentiment: Earnings call color — management discussed commercial trends and pipeline execution on the Q1 call; full transcripts provide details investors will parse for sustainability of growth. Lantheus Holdings, Inc. (LNTH) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Revenue guidance range is $1.4B–$1.5B — the top end meets street expectations but the low end is slightly light, leaving some ambiguity around FY revenue growth profile. Lantheus NASDAQ: LNTH Surprises With Q1 CY2026 Sales
• Negative Sentiment: Underlying growth is modest — Q1 revenue was up just ~1.2% year‑over‑year and reported EPS is slightly below last year’s $1.53, highlighting that near‑term organic growth remains a concern for some investors. Lantheus Holdings: Q1 Earnings Snapshot

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.